These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28075018)

  • 21. c-MET kinase inhibitors: a patent review (2011 - 2013).
    Zhu K; Kong X; Zhao D; Liang Z; Luo C
    Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A simple view on lung cancer biology: the MET pathway].
    Ruppert AM; Beau-Faller M; Belmont L; Lavolé A; Gounant V; Cadranel J; Wislez M
    Rev Mal Respir; 2011 Dec; 28(10):1241-9. PubMed ID: 22152933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma.
    Ghanaatgar-Kasbi S; Khorrami S; Avan A; Aledavoud SA; Ferns GA
    Curr Pharm Des; 2018; 24(39):4619-4625. PubMed ID: 30636579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
    Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
    Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
    Cañadas I; Rojo F; Taus Á; Arpí O; Arumí-Uría M; Pijuan L; Menéndez S; Zazo S; Dómine M; Salido M; Mojal S; García de Herreros A; Rovira A; Albanell J; Arriola E
    Clin Cancer Res; 2014 Feb; 20(4):938-50. PubMed ID: 24284055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
    Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?
    Gambella M; Palumbo A; Rocci A
    Expert Rev Mol Diagn; 2015; 15(7):881-93. PubMed ID: 25967746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical and functional significance of c-Met in breast cancer: a review.
    Ho-Yen CM; Jones JL; Kermorgant S
    Breast Cancer Res; 2015 Apr; 17(1):52. PubMed ID: 25887320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance to targeted cancer drugs through hepatocyte growth factor signaling.
    Heynen GJ; Fonfara A; Bernards R
    Cell Cycle; 2014; 13(24):3808-17. PubMed ID: 25426675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in the discovery of small molecule c-Met Kinase inhibitors.
    Parikh PK; Ghate MD
    Eur J Med Chem; 2018 Jan; 143():1103-1138. PubMed ID: 29157685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
    Chen L; Li C; Zhu Y
    Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarker development in MET-targeted therapy.
    Zhang Y; Du Z; Zhang M
    Oncotarget; 2016 Jun; 7(24):37370-37389. PubMed ID: 27013592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the HGF/Met signaling pathway in cancer therapy.
    Cecchi F; Rabe DC; Bottaro DP
    Expert Opin Ther Targets; 2012 Jun; 16(6):553-72. PubMed ID: 22530990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. C-MET inhibitors in the treatment of lung cancer.
    Goździk-Spychalska J; Szyszka-Barth K; Spychalski L; Ramlau K; Wójtowicz J; Batura-Gabryel H; Ramlau R
    Curr Treat Options Oncol; 2014 Dec; 15(4):670-82. PubMed ID: 25266653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
    Kawakami H; Okamoto I
    Gastric Cancer; 2016 Jul; 19(3):687-95. PubMed ID: 26690587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.
    Shojaei F; Lee JH; Simmons BH; Wong A; Esparza CO; Plumlee PA; Feng J; Stewart AE; Hu-Lowe DD; Christensen JG
    Cancer Res; 2010 Dec; 70(24):10090-100. PubMed ID: 20952508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the HGF/Met signalling pathway in cancer.
    Cecchi F; Rabe DC; Bottaro DP
    Eur J Cancer; 2010 May; 46(7):1260-70. PubMed ID: 20303741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Met as a therapeutic target in HCC: facts and hopes.
    Giordano S; Columbano A
    J Hepatol; 2014 Feb; 60(2):442-52. PubMed ID: 24045150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cellular and molecular mechanisms of HGF/Met in the cardiovascular system.
    Gallo S; Sala V; Gatti S; Crepaldi T
    Clin Sci (Lond); 2015 Dec; 129(12):1173-93. PubMed ID: 26561593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.